Development and clinical application of disease modifying drug for Alzheimer's Disease

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09306
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: Hirosaki University
• Principal Investigator: Shoji Mikio 弘前大学, 医学研究科, 教授 (60171021)
• Co-Investigator(Renkei-kenkyūsha): Kawarabayashi Takeshi 弘前大学, 大学院医学研究科, 准教授 (90186156) ; Nakamura Takumi 弘前大学, 医学部附属病院, 助手 (80744193)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 認知症 / Alzheimer病 / 脳アミロイド / Abeta / 認知機能 / 病理 / ELISA / Western blot

Outline of Final Research Achievements

Alzheimer's disease (AD) is the major cause of dementia. To clarify the pathogenesis and development of disease modifyed drugs (DMD) of AD, we studied effects of oral immunization of recombinant soybean consisting of Abeta epitope (Abeta+) in AD model mice TgCRND8. Induction of anti-Abeta antibodies, prevention of memory decline and Abeta plaque accumulation. Abeta oligomer was also suppressed. No adverse reactions were observed. Thus, Abuta+ is promissing DMT. In study of Hirosaki Family, we found 43 AD patients out of total 285 family members, mean onset age is 48 years of Age and duration is about 10 years.

Free Research Field

神経内科学